NASDAQ: QTTBQ32 Bio Inc Stock
$24.38+0.26 (+1.08%)
Updated Apr 18, 2024
QTTB Price
$24.38
Fair Value Price
-$2.28
Market Cap
$78.74M
52 Week Low
$8.24
52 Week High
$30.92
P/E
-0.69x
P/B
1.08x
P/S
30.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.16M
Earnings
-$112.96M
Gross Margin
100%
Operating Margin
-9,771.71%
Profit Margin
-9,771.7%
Debt to Equity
0.16
Operating Cash Flow
-$96M
Beta
1.19
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
QTTB Overview
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how QTTB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QTTB ($24.38) is overvalued by 1,169.5% relative to our estimate of its Fair Value price of -$2.28 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
QTTB ($24.38) is not significantly undervalued (1,169.5%) relative to our estimate of its Fair Value price of -$2.28 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
QTTB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QTTB due diligence checks available for Premium users.
Be the first to know about important QTTB news, forecast changes, insider trades & much more!
QTTB News
Valuation
QTTB fair value
Fair Value of QTTB stock based on Discounted Cash Flow (DCF)
Price
$24.38
Fair Value
-$2.28
Undervalued by
1,169.50%
QTTB ($24.38) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QTTB ($24.38) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QTTB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QTTB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.69x
Industry
15.68x
Market
41.33x
QTTB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.08x
Industry
5.76x
QTTB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QTTB's financial health
Profit margin
Revenue
$0.0
Net Income
-$16.1M
Profit Margin
0%
QTTB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
QTTB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$84.6M
Liabilities
$11.6M
Debt to equity
0.16
QTTB's short-term assets ($83.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QTTB's short-term assets ($83.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QTTB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
QTTB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.6M
Investing
$31.7M
Financing
$14.0k
QTTB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QTTB vs Biotech Stocks
Q32 Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.